Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of YL-90148 versus allopurinol in primary gout with hyperuricemia
CTR20222473Phase 3Active
- Sponsor
- Yingli Pharma
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of puliginurad in gout, hyperuricemia, sponsored by Yingli Pharma. Started Feb 2023; status: active.
02
Drugs
puliginurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on CTR20222473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222473.